ClinicalTrials.gg
CompletedNCT02741245Updated May 16, 2024Results posted

A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)

A Phase 3 interventional study of Ezetimibe 10 mg and Rosuvastatin 2.5 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
28th of 97
321 · median 148
Started
2016
with 3 others
Phase 3
50 of 98
1 open now
Registered
75th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 28th largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2016, is one of 50 in phase 3, and was the 75th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety and tolerability of 2 dose levels of MK-0653H in Japanese participants. The primary hypotheses are that the administration of MK-0653H is safe and tolerable and that MK-0653H is superior to single entity of Ezetimibe and Rosuvastatin in percent reduction from baseline in low-density lipoprotein-cholesterol (LDL-C) after 12 weeks of treatment.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese
  • Outpatient with hypercholesterolemia
  • Female participant who is of has to agree to remain abstinent or use (or partner use) two acceptable methods of from date of signed to the 14 days after the last dose of study drug
  • Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension (treated or untreated)
  • Uncontrolled type 1 or type 2 diabetes mellitus
  • History of coronary artery disease (CAD), CAD-equivalent disease
  • Familial hypercholesterolemia or has undergone LDL apheresis
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
  • Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption
  • History of cancer within the past 5 years (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)
  • (HIV) positive
  • History of drug/ alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Consumes more than 25 g of alcohol per day
  • Currently following an excessive weight reduction diet
  • Currently engages in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study
  • or intolerance to Ezetimibe or Rosuvastatin
  • Myopathy or rhabdomyolysis with Ezetimibe or any statin
  • Pregnant or lactating
  • Taking any other drugs and/or has taken any investigational drugs within 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
321 participants (actual)

Study arms

  • Active comparator
    Ezetimibe 10 mg

    1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks

    Drug: Ezetimibe 10 mg · Drug: Placebo for Rosuvastatin

  • Active comparator
    Rosuvastatin 2.5 mg

    1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.

    Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Ezetimibe · Drug: Placebo for Rosuvastatin

  • Active comparator
    Rosuvastatin 5.0 mg

    2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.

    Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Ezetimibe

  • Experimental
    Ezetimibe 10 mg+ Rosuvastatin 2.5 mg

    1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.

    Drug: Ezetimibe 10 mg · Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Rosuvastatin

  • Experimental
    Ezetimibe 10 mg+ Rosuvastatin 5.0 mg

    1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.

    Drug: Ezetimibe 10 mg · Drug: Rosuvastatin 2.5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)

    Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated. Results were reported as a M-estimate.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Who Experience at Least 1 Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized

    Time frame: up to 14 weeks

  3. Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event

    An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that had study drug discontinued due to an AE was summarized.

    Time frame: up to 12 weeks

  4. Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs

    Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.

    Time frame: up to 14 weeks

  5. Percentage of Participants Who Experience 1 or More Gallbladder-related AEs

    Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.

    Time frame: up to 14 weeks

  6. Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs

    Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.

    Time frame: up to 14 weeks

  7. Percentage of Participants Who Experience 1 or More Hepatitis-related AEs

    Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.

    Time frame: up to 14 weeks

  8. Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)

    Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.

    Time frame: up to 12 weeks

  9. Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

    Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L..

    Time frame: up to 12 weeks

  10. Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

    Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

    Time frame: up to 12 weeks

  11. Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)

    Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.

    Time frame: up to 12 weeks

  12. Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)

    Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 5x ULN or greater were recorded. The AST ULN was 40 U/L.

    Time frame: up to 12 weeks

  13. Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)

    Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.

    Time frame: up to 12 weeks

  14. Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)

    Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 10x ULN or greater were recorded. The AST ULN was 40 U/L.

    Time frame: up to 12 weeks

  15. Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)

    Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

    Time frame: up to 12 weeks

  16. Percentage of Participants With Potential Hy's Law Condition

    Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkalinephosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.

    Time frame: up to 12 weeks

  17. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN

    Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 12 weeks

  18. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms

    Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 12 weeks

  19. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms

    Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 12 weeks

07

Results

Posted Mar 9, 2018

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Started3572717172
Completed3571716770
Not completed01042
Withdrew: Adverse event00022
Withdrew: Protocol violation01010
Withdrew: Withdrawal by subject00010

Outcome measures

PrimaryPercentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)

Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated. Results were reported as a M-estimate.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage Change
Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)
Percentage ChangeEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)-18.7 (-21.9 to -15.5)-39.8 (-42.0 to -37.5)-47.2 (-49.4 to -44.9)-54.6 (-56.9 to -52.3)-60.5 (-62.8 to -58.2)
Statistical analysis
  • Ezetimibe 10 mg vs Ezetimibe 10 mg+ Rosuvastatin 2.5 mg · Shapiro-Wilk test · p = <0.001 · Difference in m-estimates: -35.9 · 95% CI -39.9 to -32.0Robust regression model with terms for treatment, risk category and baseline, after imputing missing values by a multiple imputation approach
  • Rosuvastatin 2.5 mg vs Ezetimibe 10 mg+ Rosuvastatin 2.5 mg · Shapiro-Wilk test · p = <0.001 · Difference in m-estimates: -14.8 · 95% CI -18.0 to -11.6
  • Ezetimibe 10 mg vs Ezetimibe 10 mg+ Rosuvastatin 5.0 mg · Shapiro-Wilk test · p = <0.001 · Difference in m-estimates: -41.8 · 95% CI -45.8 to -37.9
  • Rosuvastatin 5.0 mg vs Ezetimibe 10 mg+ Rosuvastatin 5.0 mg · Shapiro-Wilk test · p = <0.001 · Differecne in m-estimates: -13.3 · 95% CI -16.6 to -10.1
PrimaryPercentage of Participants Who Experience at Least 1 Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized

Time frame:
up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)31.434.742.340.837.5
PrimaryPercentage of Participants Who Had Study Drug Discontinued Due to Adverse Event

An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that had study drug discontinued due to an AE was summarized.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event
Percentage of participantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event0.00.00.02.81.4
PrimaryPercentage of Participants Who Experience 1 or More Gastrointestinal-related AEs

Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.

Time frame:
up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs0.06.94.28.52.8
PrimaryPercentage of Participants Who Experience 1 or More Gallbladder-related AEs

Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.

Time frame:
up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience 1 or More Gallbladder-related AEs0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs

Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.

Time frame:
up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs0.01.44.22.82.8
PrimaryPercentage of Participants Who Experience 1 or More Hepatitis-related AEs

Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.

Time frame:
up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience 1 or More Hepatitis-related AEs0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)

Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)0.00.00.01.40.0
PrimaryPercentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L..

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)0.00.00.01.40.0
PrimaryPercentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)

Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)

Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 5x ULN or greater were recorded. The AST ULN was 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)

Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)

Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 10x ULN or greater were recorded. The AST ULN was 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)

Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)0.00.00.00.00.0
PrimaryPercentage of Participants With Potential Hy's Law Condition

Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkalinephosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Potential Hy's Law Condition
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants With Potential Hy's Law Condition0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN

Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms

Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms0.00.00.00.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms

Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 12 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms
Percentage of ParticipantsEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms0.00.00.00.00.0

Adverse events

Collected over up to 2 weeks post last dose of study drug (up to 14 weeks total). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe 10 mg0/35 (0%)0/35 (0%)6/35 (17.1%)
Rosuvastatin 2.5 mg0/72 (0%)0/72 (0%)8/72 (11.1%)
Rosuvastatin 5.0 mg0/71 (0%)1/71 (1.4%)11/71 (15.5%)
Ezetimibe 10 mg+ Rosuvastatin 2.5 mg0/71 (0%)0/71 (0%)6/71 (8.5%)
Ezetimibe 10 mg+ Rosuvastatin 5.0 mg0/72 (0%)0/72 (0%)7/72 (9.7%)
Most frequent serious events
Most frequent serious events
EventEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
Bacterial prostatitisInfections and infestations0/350/721/710/710/72
Most frequent other events
Most frequent other events
EventEzetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mg
NasopharyngitisInfections and infestations6/358/7211/716/717/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ezetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mgTotal
Mean56.0 ± 8.955.7 ± 10.658.9 ± 9.056.0 ± 10.358.2 ± 10.657.0 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mgTotal
Female1636403737166
Male1936313435155
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ezetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mgTotal
American Indian or Alaska Native000000
Asian3572717172321
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ezetimibe 10 mgRosuvastatin 2.5 mgRosuvastatin 5.0 mgEzetimibe 10 mg+ Rosuvastatin 2.5 mgEzetimibe 10 mg+ Rosuvastatin 5.0 mgTotal
American Indian or Alaska Native000000
Asian3572717172321
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Teramoto T, Yokote K, Nishida C, Oshima N, Takase T. A phase III clinical trial to study the efficacy and safety of ezetimibe plus rosuvastatin combination therapy in Japanese patients with hypercholesterolemia - A randomized, double-blind comparative study. J Clin Therapeut Med. 2017;33(11):881-896.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jan 2017, 7 months.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2016
First posted
Apr 18, 2016
StartActual
Jun 9, 2016
Primary completionActual
Jan 18, 2017
CompletionActual
Jan 18, 2017
Results first posted
Mar 9, 2018
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02741245
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 18, 2016
Start date
Jun 9, 2016
Primary completion
Jan 18, 2017
Completion
Jan 18, 2017
Results posted
Mar 9, 2018
Last update
May 16, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Rosuvastatin

Start the discussion